跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Rigel Pharmaceuticals, Inc.

首页临床试验发起方与机构Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

ACTIVE

611 Gateway Blvd Ste 900, 加利福尼亚州圣马特奥县, California, 美国www.rigel.comPublic147 名员工成立于: 1996-01-012亿美元

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

61

54 进行中

药物批准

4

批准总数

监管机构

1

监管机构数

成立时间

1996

概览

试验阶段分布

阶段

试验数

占比

1 期

45

73.8%

3 期

2

3.3%

不适用

1

1.6%

试验状态分布

进行中（未招募）

54

88.5%

已完成

7

11.5%

相关临床试验

该机构主办的试验（61）

This is a Phase 3 multi-center, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in increasing hemoglobin in subjects with warm antibody autoimmune hemolytic anemia (wAIHA) who have failed at least one prior treatment regimen.

进行中（未招募）

Mar 202281 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Jul 202181 名受试者

This is a Phase 3 multi-center, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in increasing hemoglobin in subjects with warm antibody autoimmune hemolytic anemia (wAIHA) who have failed at least one prior treatment regimen.

进行中（未招募）

Jan 202181 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Jan 202190 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Feb 202090 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Feb 202081 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Jan 202081 名受试者

This is a Phase 3 multi-center, open-label extension study to evaluate the long-term safety and efficacy of fostamatinib (R788) in subjects with wAIHA who have completed 24 weeks of participation in study C-935788-057.

进行中（未招募）

Jan 202090 名受试者

第 1 页，共 8 页

药物批准

按机构分类的批准

FDA

Food and Drug Administration

4

药物批准

近期批准

资讯

TAVALISSE® (Fostamatinib) Approved in Mexico for Chronic ITP Treatment

- Knight Therapeutics' Mexican affiliate receives regulatory approval for TAVALISSE® (fostamatinib) from COFEPRIS to treat thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP). - Fostamatinib, an orally administered spleen tyrosine kinase (SYK) inhibitor, offers a new therapeutic alternative for patients who have had an insufficient response to previous ITP treatments. - The approval marks a significant step in expanding treatment options for ITP patients in Latin America, with the launch of TAVALISSE® in Mexico expected in the first half of 2026.

本页目录

概览
相关临床试验61
药物批准4
资讯1

返回机构列表